New drug combo targets tough breast cancer subtype in phase 3 trial
NCT ID NCT05806060
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug VEGFR BP102 to standard chemotherapy (nab-paclitaxel) helps people with a specific, hard-to-treat form of advanced triple-negative breast cancer (called BLIS subtype). About 134 participants who have not had prior treatment for metastatic disease will be enrolled. The main goal is to see if the combination delays cancer growth compared to chemotherapy alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL-LIKE IMMUNE SUPPRESSED SUBTYPE OF TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Breast cancer institute of Fudan University Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could an oral chemo pill improve breast cancer treatment?
- Can a new nucleotide analogue boost cancer treatment?